Content

Section 1: Basic Science

Soumik Goswami, Sreenivasa Murthy L, Rakesh Kumar Sahay, Vijay Viswanathan

1. Liver Iron Concentration is an Independent Risk Factor for the Prediabetic State in β-thalassemia Patients 1
2. Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Ceramides 2
3. Taking a Brown Adipose Tissue to the Chains of Diabetes 4
4. The *TCF7L2* Locus: A Genetic Window into the Pathogenesis of Type 1 and Type 2 Diabetes 5
5. Glycemic Index of Wheat and Rice are Similar when Consumed as Part of a North Indian Mixed Meal 7
6. *MACF1* Gene Variant rs2296172 is Associated with Type 2 Diabetes Susceptibility in Mizo Population from Northeast India 8
7. Copeptin, a Surrogate Marker for Arginine Vasopressin Secretion, is Positively Associated with Glucagon 10
8. PAX Proteins and Their Role in Pancreas 11
9. What has Zinc Transporter 8 Autoimmunity Taught us About Type 1 Diabetes? 13

Section 2: Epidemiology

Chitra Selvan, Jugal Kishor Sharma, Anand Moses, Vijay Kumar Panikar

1. Association of Maternal Lactation with Diabetes and Hypertension: A Systematic Review and Meta-analysis 15
2. Prevalence and Predictors of Osteopenia and Osteoporosis in Patients with Type 2 Diabetes Mellitus: A Cross-sectional Study From a Tertiary Care Institute in North India 16
3. Autoantibody Reversion: Changing Risk Categories in Multiple-autoantibody-positive Individuals 18
4. Incidence and Associations of Chronic Kidney Disease in Community Participants with Diabetes: A 5-year Prospective Analysis of the EXTEND45 Study 19
5. Establishment and Validation of a Risk Prediction Model for Early Diabetic Kidney Disease Based on a Systematic Review and Meta-analysis of 20 Cohorts 21

6. Every Fifth Individual with Type 1 Diabetes Suffers from an Additional Autoimmune Disease: A Finnish Nationwide Study 22
7. Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons from a 5-year Pediatric Swedish National Cohort Study 24
8. Effect of Age at Menarche on Microvascular Complications Among Women with Type 1 Diabetes 26
9. Geographic Variation and Associated Covariates of Diabetes Prevalence in India 28
10. Sex Differences in the Burden of Type 2 Diabetes and Cardiovascular Risk Across the Life Course 30
11. Incidence of New-onset Diabetes and Post-transplant Metabolic Syndrome after Liver Transplantation - A Prospective Study from South India 31
12. Use of Antihyperglycemic Medications in U.S. Adults: An Analysis of the National Health and Nutrition Examination Survey 33
13. Why are South Asians Prone to Type 2 Diabetes? A Hypothesis Based on Underexplored Pathways 34
14. Prevalence and Clinical Characteristics of Individuals with Newly Detected Lean Diabetes in Tamil Nadu, South India: A Community-based Cross-sectional Study 36
15. Prevalence of Diabetes Mellitus in 2019 Novel Coronavirus: A Meta-analysis 37
16. Vitamin D Supplementation and Prevention of Type 2 Diabetes 38
17. Prognostic Significance of Long-term HbA1c Variability for All-cause Mortality in the ACCORD Trial 40
18. Evaluating the Performance of the Indian Diabetes Risk Score in Different Ethnic Groups 42

Section 3: Comorbidities

Amritava Ghosh, Shalini Jaggi, Mithun Bhartia, Bikash Bhattacharjee

1. Usefulness of Routine Fractional Flow Reserve for Clinical Management of Coronary Artery Disease in Patients with Diabetes 44
2. The Long-term Effects of Metformin on Patients with Type 2 Diabetic Kidney Disease 46
3. Impact of Treating Oral Disease on Preventing Vascular Diseases: A Model-based Cost-effectiveness Analysis of Periodontal Treatment Among Patients with Type 2 Diabetes 48
4. Risk of Rapid Kidney Function Decline, All-cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes 49
5. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients with Type 2 Diabetes 51
6. Time in Range is Associated with Carotid Intima-media Thickness in Type 2 Diabetes 53

Section 4: Complications

Indira Maisnam, Amit Gupta, Neeta Deshpande, Brij Mohan Makkar

1. Reduced Pancreatic Polypeptide Response is Associated with Early Alteration of Glycemic Control in Chronic Pancreatitis 56
2. Young-onset Type 2 Diabetes and Younger Current Age: Increased Susceptibility to Retinopathy in Contrast to other Complications 58
3. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid among Patients with Type 2 Diabetes 60
4. Seroprevalence and Risk Factors Associated with HBV and HCV Infection among Subjects with Type 2 Diabetes from South India 62
5. Prevalence and Patterns of Cardiac Autonomic Dysfunction in Male Patients with Type 2 Diabetes Mellitus and Chronic Charcot's Neuroarthropathy: A Cross-sectional Study from South India 64
6. Longitudinal Associations between Depression and Diabetes Complications: A Systematic Review and Meta-analysis 66
7. Bone Histomorphometry in Young Patients with Type 2 Diabetes is Affected by Disease Control and Chronic Complications 68
8. Teriparatide [Recombinant Human Parathyroid Hormone (1-34)] Increases Foot Bone Remodeling in Diabetic Chronic Charcot Neuroarthropathy: A Randomized Double-blind Placebo-controled Study 70

Section 5: Type 1 Diabetes Mellitus

Ajitesh Roy, Archana Sarda, Banshi Saboo, Ch Vasanth Kumar

1. Immune Checkpoint Inhibitor-induced Type 1 Diabetes: A Systematic Review and Meta-analysis 75
2. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes 77
3. Profile of Auto-antibodies (Disease Related and Other) in Children with Type 1 Diabetes 80
4. Biomarker Panels Associated with Progression of Renal Disease in Type 1 Diabetes 82
5. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults with Type 1 Diabetes: A Randomized Clinical Trial 84
6. Continuous Glucose Monitoring in People with Type 1 Diabetes on Multiple-dose Injection Therapy: The Relationship between Glycemic Control and Hypoglycemia 86
7. The Efficacy of Technology in Type 1 DM: A Systemic Review, Network Meta-analysis, and Narrative Synthesis 88
8. Use of Sensor-integrated Pump Therapy to Reduce Hypoglycemia in People with Type 1 Diabetes: A Real-world Study in the UK 90

Section 6: Gestational Diabetes Mellitus

Rana Bhattacharjee, Purvi Chawla, Sunil Surajprasad Gupta, Rajeev Chawla

1. Prevention of Gestational Diabetes Mellitus in Overweight or Obese Pregnant Women: A Network Meta-analysis 95
2. Maternal Age and the Risk of Gestational Diabetes Mellitus: A Systematic Review and Meta-analysis of Over 120 Million Participants 96
3. Gestational Diabetes Mellitus in HIV-infected Pregnant Women: A Systematic Review and Meta-analysis 98
4. Continuous Glucose Monitoring in Pregnancy: Importance of Analyzing Temporal Profiles to Understand Clinical Outcomes 99
5. Urinary and Serum Angiogenic Markers in Women with Pre-existing Diabetes During Pregnancy and their Role in Pre-eclampsia Prediction 101

Section 7: Drugs and Therapeutics

Sayantan Ray, Pratap Jethwani, Anuj Maheshwari, Sudhir Bhandari

1. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients with Heart Failure with and without Diabetes 105
2. Glycemic Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonist on Top of Sodium-glucose Cotransporter-2 Inhibitor Treatment Compared to Sodium-glucose Cotransporter-2 Inhibitor Alone: A Systematic Review and Meta-analysis of Randomized Controlled Trials 107
3. Once-weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment 109
4. Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-ranging Study 111
5. Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight 113
6. Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-blinded, Placebo-controlled Study 114
7. Hypoglycemia is Reduced with Use of Inhaled Technosphere® Insulin Relative to Insulin Aspart in Type 1 Diabetes Mellitus 116
8. Systematic Review and Meta-analysis of Clinical Trials Examining the Effect of Hyperbaric Oxygen Therapy in People with Diabetes-related Lower Limb Ulcers 118
9. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes 119
10. Effects of Probiotic Supplementation during Pregnancy on Metabolic Outcomes: A Systematic Review and Meta-analysis of Randomized Controlled Trials 121
11. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction 122
12. Associations between Metformin Use and Vitamin B12 Levels, Anemia, and Neuropathy in Patients with Diabetes: A Meta-analysis 124
13. Risk of Severe Hypoglycemia and its Impact in Type 2 Diabetes in DEVOTE 126

14. Switching to Degludec is Associated with Reduced Hypoglycemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational Study 127
15. A Survey of Physician Experience and Treatment Satisfaction using Fast-acting Insulin aspart in People with Type 1 or Type 2 Diabetes 128
16. A Randomized Trial Evaluating the Efficacy and Safety of Fast-acting Insulin Aspart Compared with Insulin Aspart, Both in Combination with Insulin Degludec with or without Metformin, in Adults with Type 2 Diabetes (Onset 9) 130
17. Oral Semaglutide versus Empagliflozin in Patients with Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial 131
18. Efficacy, Safety, and Tolerability of Oral Semaglutide versus Placebo Added to Insulin with or without Metformin in Patients with Type 2 Diabetes: The PIONEER 8 Trial 133
19. Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-naïve Patients with Type 2 Diabetes after Failure of Oral Therapy in a Real-world Setting 135
20. An Assessment of Physician Reasons for Prescribing Insulin Lispro 200 units/mL in Germany 136
21. Cardiovascular and Kidney Outcomes of Linagliptin Treatment in Older People with Type 2 Diabetes and Established Cardiovascular Disease and/or Kidney Disease: A Prespecified Subgroup Analysis of the Randomized, Placebo-controlled CARMELINA® trial 138
22. Linagliptin and Cardiorenal Outcomes in Asians with Type 2 Diabetes Mellitus and Established Cardiovascular and/or Kidney Disease: Subgroup Analysis of the Randomized CARMELINA® Trial 139
23. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium-glucose Cotransporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-blind, Active-controlled Trial 141
24. An Open-label, Single-period, Two-stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250 mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions 143
25. Efficacy of Empagliflozin on Heart Failure and Renal Outcomes in Patients with Atrial Fibrillation: Data from the EMPA-REG OUTCOME Trial 144
26. Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial 146
27. Suboptimal Glycemic Control among Subjects with Diabetes Mellitus in India: A Subset Analysis of Cross-sectional Wave-7 (2016) Data from the International Diabetes Management Practices Study (IDMPS) 148
28. A Practitioner's Toolkit for Insulin Motivation in Adults with Type 1 and Type 2 Diabetes Mellitus: Evidence-based Recommendations from an International Expert Panel 149
29. Impact of Baseline Characteristics and Beta-cell Function on the Efficacy and Safety of Subcutaneous Once-weekly Semaglutide: A Patient-level, Pooled Analysis of the SUSTAIN 1-5 Trials 151
30. Efficacy and Safety of Once-weekly Semaglutide versus Daily Canagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes (SUSTAIN 8): A Double-blind, Phase 3b, Randomized Controlled Trial 153

Section 8: Newer Technologies and Future Directions

Partha P Chakraborty, Sanjay Reddy, Jothydev Kesavade, Sanjay Agarwal

1. Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review with Meta-analysis of Randomized Controlled Trials 160
2. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time in Range 162
3. Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group 163
4. Systematic Review of Randomized Controlled Trials Evaluating Glycemic Efficacy and Patient Satisfaction of Intermittent-scanned Continuous Glucose Monitoring in Patients with Diabetes 165
5. Serum Tenascin-C is Independently Associated with Increased Major Adverse Cardiovascular Events and Death in Individuals with Type 2 Diabetes: A French Prospective Cohort 167
6. Diabetes Screening: Detection and Application of Saliva 1,5-Anhydroglucitol by Liquid Chromatography-mass Spectrometry 168
7. Circulating Retinol-binding Protein 4 is Inversely Associated with Pancreatic β-cell Function Across the Spectrum of Glycemia 170
8. Positioning Time in Range in Diabetes Management 171
9. Neprilysin Inhibition: A New Therapeutic Option for Type 2 Diabetes? 173
10. Early Pregnancy Prediction of Gestational Diabetes Mellitus Risk using Prenatal Screening Biomarkers in Nulliparous Women 174
11. Six-month Randomized, Multicenter Trial of Closed-loop Control in Type 1 Diabetes 176

Index **179**